{"id":"megestrol","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Impotence","drugRate":"7.8%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"7.1%","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"5.6%","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"4.1%","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"2.8%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"4.3%","severity":"common","organSystem":""},{"effect":"Anemia","drugRate":"2.6%","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"3.4%","severity":"common","organSystem":""},{"effect":"Libido Decreased","drugRate":"2.3%","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"2.8%","severity":"common","organSystem":""},{"effect":"Hyperglycemia","drugRate":"2.6%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"3.4%","severity":"common","organSystem":""},{"effect":"Pain","drugRate":"3.1%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"3.9%","severity":"common","organSystem":""},{"effect":"Pneumonia","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Urinary Frequency","drugRate":"1.3%","severity":"common","organSystem":""}],"contraindications":["Adrenal cortical hypofunction","Chronic heart failure","Diabetes mellitus","Disease of liver","Hyperglycemia","Hypertensive disorder","Kidney disease","Male hypogonadism","Pregnancy, function","Thromboembolic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Pulmonary Embolism","drugRate":"","severity":"serious"},{"effect":"Thrombophlebitis","drugRate":"","severity":"serious"},{"effect":"Thromboembolic Phenomena","drugRate":"","severity":"serious"},{"effect":"Glucose Intolerance","drugRate":"","severity":"serious"},{"effect":"Cardiomyopathy","drugRate":"","severity":"serious"},{"effect":"Sarcoma","drugRate":"","severity":"serious"},{"effect":"Convulsion","drugRate":"","severity":"serious"},{"effect":"Leukopenia","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Megestrol acetate","megestrol acetate"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"582cff8a-1def-43d6-ba7e-dce49e3e9f27","title":"MEGESTROL ACETATE SUSPENSION [NATCO PHARMA USA LLC]"},"ecosystem":[],"mechanism":{"target":"Cytochrome P450 2C9, Multidrug resistance protein 1, Glucocorticoid receptor"},"_scrapedAt":"2026-03-27T23:54:23.373Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Anorexia from HIV","diseaseId":"anorexia-from-hiv","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Cachexia due to HIV","diseaseId":"cachexia-due-to-hiv","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Endometrial carcinoma","diseaseId":"endometrial-carcinoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hormone receptor positive malignant neoplasm of breast","diseaseId":"hormone-receptor-positive-malignant-neoplasm-of-breast","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nutritional deficiency associated with AIDS","diseaseId":"nutritional-deficiency-associated-with-aids","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05538897","phase":"PHASE1, PHASE2","title":"Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-31","conditions":"FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma","enrollment":96},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT07477808","phase":"PHASE3","title":"Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer","enrollment":116},{"nctId":"NCT00420563","phase":"PHASE2","title":"Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2009-09-25","conditions":"Cancer","enrollment":88},{"nctId":"NCT07319429","phase":"PHASE2, PHASE3","title":"Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Endometrial Cancer, Fertility","enrollment":260},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT04939090","phase":"PHASE3","title":"Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-01-03","conditions":"Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":360},{"nctId":"NCT07436793","phase":"PHASE2","title":"Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial","status":"NOT_YET_RECRUITING","sponsor":"New Mexico Cancer Research Alliance","startDate":"2026-03-01","conditions":"Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia","enrollment":140},{"nctId":"NCT07408505","phase":"NA","title":"Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2026-01-20","conditions":"Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome","enrollment":56},{"nctId":"NCT07391826","phase":"PHASE2","title":"Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-15","conditions":"Stage III Gastric Cancer","enrollment":48},{"nctId":"NCT06671548","phase":"PHASE3","title":"Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-01-15","conditions":"Heavy Menstrual Bleeding, Uterine Fibroids","enrollment":120},{"nctId":"NCT07377734","phase":"PHASE2","title":"A Multicenter, Randomized, Open-Label, Controlled Clinical Trial of Intrauterine Injection of Recombinant Humanized Type III Collage in the Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia","status":"NOT_YET_RECRUITING","sponsor":"Wang Jianliu","startDate":"2026-01-30","conditions":"Atypical Endometrial Hyperplasia, Endometrial Cancer","enrollment":30},{"nctId":"NCT07356037","phase":"PHASE3","title":"Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-01-10","conditions":"Cachexia, Hepatocellular Carcinoma","enrollment":68},{"nctId":"NCT04576104","phase":"PHASE2","title":"Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2021-11-29","conditions":"Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma","enrollment":51},{"nctId":"NCT07338487","phase":"PHASE1","title":"A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-01-01","conditions":"Locally Advanced Cervical Cancer, Cachexia","enrollment":88},{"nctId":"NCT03671811","phase":"PHASE2","title":"Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-01-21","conditions":"Atypical Endometrial Hyperplasia, Endometrial Carcinoma","enrollment":44},{"nctId":"NCT06998758","phase":"PHASE3","title":"Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-11-11","conditions":"Neoadjuvant Chemotherapy, Weight Loss","enrollment":60},{"nctId":"NCT07254416","phase":"PHASE4","title":"A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-15","conditions":"Breast Cancer Patients Treated With T-DXd","enrollment":120},{"nctId":"NCT07246070","phase":"PHASE2","title":"Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting","status":"NOT_YET_RECRUITING","sponsor":"AIPING ZHOU","startDate":"2025-12","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":127},{"nctId":"NCT07243379","phase":"PHASE4","title":"A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-09-25","conditions":"Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia, Multicenter Observational Study","enrollment":495},{"nctId":"NCT07168226","phase":"PHASE2","title":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","status":"NOT_YET_RECRUITING","sponsor":"MetaFines","startDate":"2025-09-30","conditions":"Cachexia; Cancer","enrollment":135},{"nctId":"NCT03815019","phase":"PHASE4","title":"iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2019-08-15","conditions":"Feeding Behavior, Feeding Disorder of Infancy or Early Childhood","enrollment":70},{"nctId":"NCT07150663","phase":"PHASE3","title":"Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-08-20","conditions":"Non-small Cell Lung Cancer","enrollment":134},{"nctId":"NCT07130617","phase":"PHASE1","title":"Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-09-29","conditions":"Efficacy, Safety, Megestrol Acetate","enrollment":132},{"nctId":"NCT07124195","phase":"PHASE3","title":"Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xinxiang Medical College","startDate":"2025-08-10","conditions":"Malignant Solid Tumors, Moderate to High Emetogenic Chemotherapy (MEC/HEC) Drugs","enrollment":126},{"nctId":"NCT05316467","phase":"PHASE2, PHASE3","title":"Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma","status":"RECRUITING","sponsor":"Xiaojun Chen","startDate":"2022-05-01","conditions":"Endometrial Carcinoma, Obese, Overweight","enrollment":89},{"nctId":"NCT04491643","phase":"PHASE2","title":"Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-09-01","conditions":"Endometrial Carcinoma Stage I","enrollment":48},{"nctId":"NCT05316493","phase":"PHASE2, PHASE3","title":"Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia","status":"RECRUITING","sponsor":"Xiaojun Chen","startDate":"2022-06-13","conditions":"Atypical Endometrial Hyperplasia, Fertility Issues, Overweight and Obesity","enrollment":172},{"nctId":"NCT07092137","phase":"PHASE2","title":"Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2025-10-10","conditions":"Lung Cancer, Cachexia-Anorexia Syndrome","enrollment":116},{"nctId":"NCT07077876","phase":"","title":"Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-06-20","conditions":"Endometrial Adenocarcinoma, Endometrial Hyperplasia, Fertility Preservation","enrollment":100},{"nctId":"NCT06963593","phase":"PHASE4","title":"Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-06-01","conditions":"Advanced Gastroesophageal Cancer","enrollment":220},{"nctId":"NCT06961201","phase":"PHASE3","title":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-05-01","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy","enrollment":94},{"nctId":"NCT06961188","phase":"PHASE3","title":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-06-01","conditions":"Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With Systemic Therapy","enrollment":174},{"nctId":"NCT06914297","phase":"PHASE2","title":"TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-21","conditions":"Endometrial Cancer","enrollment":10},{"nctId":"NCT06940102","phase":"","title":"Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-03-12","conditions":"Cachexia, Digestive System Cancer, Gastric Cancer","enrollment":120},{"nctId":"NCT05247268","phase":"PHASE2","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-03-11","conditions":"Endometrial Neoplasm Malignant Stage I","enrollment":104},{"nctId":"NCT06909383","phase":"PHASE2","title":"Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2025-06-01","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC), Cancer - Associated Anorexia - Cachexia Syndrome","enrollment":41},{"nctId":"NCT06828757","phase":"PHASE3","title":"Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2025-05-01","conditions":"Non Small Cell Lung Cancer","enrollment":94},{"nctId":"NCT06830018","phase":"NA","title":"Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-01-23","conditions":"Cancer-related Fatigue， Gastric Cancer，Colorectal Cancer，Nano-crystalline Megestrol Acetate，Megestrol Acetate，First-line Treatment","enrollment":76},{"nctId":"NCT06793228","phase":"PHASE2","title":"Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-01-15","conditions":"SCLC, Extensive Stage","enrollment":250},{"nctId":"NCT06772428","phase":"PHASE3","title":"Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-01-01","conditions":"Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors","enrollment":96},{"nctId":"NCT05255653","phase":"PHASE2, PHASE3","title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2021-11-11","conditions":"Endometrial Cancer","enrollment":1615},{"nctId":"NCT04683237","phase":"PHASE2, PHASE3","title":"Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia","status":"WITHDRAWN","sponsor":"Xiaojun Chen","startDate":"2021-03-20","conditions":"Atypical Endometrial Hyperplasia, Obese, Fertility Issues","enrollment":""},{"nctId":"NCT04607252","phase":"PHASE2, PHASE3","title":"Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia","status":"TERMINATED","sponsor":"Fudan University","startDate":"2021-01-11","conditions":"Atypical Endometrial Hyperplasia","enrollment":12},{"nctId":"NCT03241888","phase":"PHASE2, PHASE3","title":"Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia","status":"COMPLETED","sponsor":"Fudan University","startDate":"2017-07-04","conditions":"Atypical Endometrial Hyperplasia","enrollment":180},{"nctId":"NCT06549855","phase":"NA","title":"PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10","conditions":"Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency","enrollment":10},{"nctId":"NCT05913427","phase":"PHASE2","title":"Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)","status":"RECRUITING","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2022-06-08","conditions":"Adrenocortical Carcinoma","enrollment":80},{"nctId":"NCT06500234","phase":"PHASE3","title":"Nutrition Impact on Immunotherapy of Cancer","status":"RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2024-06-01","conditions":"Nutrition Disorders, Immunotherapy, Cancer","enrollment":300},{"nctId":"NCT06417736","phase":"NA","title":"Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2023-12-01","conditions":"Endometrial Cancer Stage I, Endometrial Hyperplasia","enrollment":75},{"nctId":"NCT03963752","phase":"PHASE4","title":"Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2019-08-15","conditions":"Idiopathic Precocious Puberty","enrollment":126},{"nctId":"NCT03306472","phase":"PHASE2","title":"A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-07-20","conditions":"Breast Cancer","enrollment":198},{"nctId":"NCT04491682","phase":"PHASE2, PHASE3","title":"Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-09-01","conditions":"Atypical Endometrial Hyperplasia","enrollment":36},{"nctId":"NCT00846313","phase":"NA","title":"Can Malnutrition be Prevented in Patient With Colorectal Cancer Stage Dukes D?","status":"WITHDRAWN","sponsor":"Norwegian University of Science and Technology","startDate":"2003-12","conditions":"Colorectal Neoplasm","enrollment":""},{"nctId":"NCT06147908","phase":"PHASE1","title":"Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-07-01","conditions":"Apetite Stimulants","enrollment":54},{"nctId":"NCT05332483","phase":"PHASE1","title":"Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-07-05","conditions":"Endometrial Cancer","enrollment":5},{"nctId":"NCT05945407","phase":"NA","title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2016-08-01","conditions":"Endometrial Neoplasms, Endometrial Neoplasm Malignant, Endometrial Neoplasm Malignant Stage I","enrollment":57},{"nctId":"NCT03283488","phase":"PHASE2","title":"Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2019-03-26","conditions":"Cachexia; Cancer, Anorexia","enrollment":52},{"nctId":"NCT04897217","phase":"PHASE3","title":"Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-06-30","conditions":"Endometrial Hyperplasia","enrollment":""},{"nctId":"NCT04385667","phase":"PHASE2, PHASE3","title":"LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-05-20","conditions":"Atypical Endometrial Hyperplasia","enrollment":143},{"nctId":"NCT05492487","phase":"PHASE2","title":"A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore","status":"UNKNOWN","sponsor":"KK Women's and Children's Hospital","startDate":"2020-01-03","conditions":"Endometrial Hyperplasia, Fertility Issues, Disease Regression","enrollment":60},{"nctId":"NCT03077698","phase":"PHASE2","title":"An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer","status":"TERMINATED","sponsor":"Xenetic Biosciences, Inc.","startDate":"2017-06-14","conditions":"Endometrial Cancer","enrollment":25},{"nctId":"NCT05380479","phase":"PHASE2","title":"Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2022-06-01","conditions":"Anorexia","enrollment":80},{"nctId":"NCT02269670","phase":"PHASE2","title":"Phase II Study of Everolimus Beyond Progression","status":"TERMINATED","sponsor":"Emory University","startDate":"2014-11-25","conditions":"Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer","enrollment":3},{"nctId":"NCT00001079","phase":"PHASE2","title":"A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Wasting Syndrome","enrollment":80},{"nctId":"NCT01968317","phase":"PHASE2","title":"Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma","status":"COMPLETED","sponsor":"Xiaojun Chen","startDate":"2013-10","conditions":"Endometrial Atypical Hyperplasia, Endometrial Adenocarcinoma","enrollment":150},{"nctId":"NCT00070148","phase":"PHASE3","title":"Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2004-03-01","conditions":"Unspecified Adult Solid Tumor, Protocol Specific, Weight Changes","enrollment":155},{"nctId":"NCT00031785","phase":"PHASE3","title":"Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2000-09-01","conditions":"Anorexia, Cachexia, Lung Cancer","enrollment":25},{"nctId":"NCT00006799","phase":"PHASE3","title":"Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2000-10-01","conditions":"Anorexia, Cachexia, Head and Neck Cancer","enrollment":13},{"nctId":"NCT02556619","phase":"NA","title":"Randomized Control Trial (RCT) of Early Palliative Care for HCC","status":"UNKNOWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-04-02","conditions":"Carcinoma, Hepatocellular","enrollment":72},{"nctId":"NCT02644408","phase":"PHASE3","title":"Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2014-10-01","conditions":"Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma","enrollment":184},{"nctId":"NCT03241914","phase":"PHASE2, PHASE3","title":"Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2017-07-04","conditions":"Endometrial Neoplasm Malignant Stage I","enrollment":64},{"nctId":"NCT00503581","phase":"PHASE2","title":"Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia","status":"TERMINATED","sponsor":"Gynecologic Oncology Group","startDate":"2007-07","conditions":"High Grade Squamous Intraepithelial Neoplasia, Stage 0 Uterine Corpus Cancer","enrollment":9},{"nctId":"NCT04430361","phase":"PHASE2","title":"the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2018-09-07","conditions":"Tumor, Chemotherapy-induced Nausea and Vomiting","enrollment":120},{"nctId":"NCT02595723","phase":"PHASE4","title":"Phenytoin for Memory Impairment Secondary to Megestrol","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2015-07","conditions":"Cognitive Impairment","enrollment":21},{"nctId":"NCT03024580","phase":"PHASE2","title":"A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2017-03-06","conditions":"Breast Neoplasm","enrollment":20},{"nctId":"NCT04046185","phase":"EARLY_PHASE1","title":"Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer","status":"UNKNOWN","sponsor":"Shanghai First Maternity and Infant Hospital","startDate":"2019-10-01","conditions":"Endometrial Cancer Stage I","enrollment":60},{"nctId":"NCT00729586","phase":"PHASE2","title":"Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-09","conditions":"Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer","enrollment":73},{"nctId":"NCT00910091","phase":"PHASE2","title":"The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"Ipsen","startDate":"2009-08","conditions":"Endometrial Cancer","enrollment":73},{"nctId":"NCT03777930","phase":"PHASE4","title":"The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol","status":"UNKNOWN","sponsor":"Shenzhen Fifth People's Hospital","startDate":"2018-12-10","conditions":"Cancer, Therapy-Related","enrollment":200},{"nctId":"NCT00483327","phase":"PHASE2","title":"Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2007-06","conditions":"Atypical Endometrial Hyperplasia, Endometrial Carcinoma","enrollment":31},{"nctId":"NCT00637572","phase":"PHASE2","title":"Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2004-12","conditions":"HIV Infections, Cachexia, Anorexia","enrollment":63},{"nctId":"NCT00584857","phase":"PHASE2","title":"A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2004-07","conditions":"Uterine Cancer","enrollment":30},{"nctId":"NCT02064725","phase":"PHASE2","title":"Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA","status":"UNKNOWN","sponsor":"Kevelt AS","startDate":"2014-09","conditions":"Recurrent or Persistent Endometrial Carcinoma","enrollment":8},{"nctId":"NCT02980653","phase":"PHASE2","title":"Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT","status":"UNKNOWN","sponsor":"TTY Biopharm","startDate":"2015-05","conditions":"Head and Neck Cancer","enrollment":105},{"nctId":"NCT02990728","phase":"PHASE2","title":"Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2016-03","conditions":"Endometrial Cancer","enrollment":120},{"nctId":"NCT00637403","phase":"PHASE1","title":"Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension","status":"TERMINATED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2006-05","conditions":"Healthy","enrollment":7},{"nctId":"NCT01035229","phase":"PHASE3","title":"Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Carcinoma","enrollment":546},{"nctId":"NCT01206478","phase":"PHASE2","title":"Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age","status":"COMPLETED","sponsor":"Ann Davis, PhD, MPH, ABPP","startDate":"2010-08","conditions":"Chronic Oral Food Refusal","enrollment":21},{"nctId":"NCT00031707","phase":"PHASE3","title":"Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2000-03","conditions":"Anorexia, Cachexia","enrollment":429},{"nctId":"NCT00637728","phase":"PHASE3","title":"Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients","status":"TERMINATED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2006-06","conditions":"Anorexia, Cachexia, Weight Loss","enrollment":5},{"nctId":"NCT00637806","phase":"PHASE3","title":"Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension","status":"TERMINATED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2006-06","conditions":"Anorexia, Cachexia, Weight Loss","enrollment":4},{"nctId":"NCT00638079","phase":"PHASE1","title":"Evaluating the Effect of Food on Absorption of Megace ES","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2006-06","conditions":"Pharmacokinetics, Bioavailability, Absorption","enrollment":24},{"nctId":"NCT02619266","phase":"PHASE2, PHASE3","title":"The Safety and Effect Study of Acupuncture for Anorexia in Patients With Gastrointestinal Tract and Lung Cancers","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2015-12","conditions":"Anorexia, Cancer Cachexia","enrollment":160},{"nctId":"NCT01200602","phase":"PHASE2","title":"Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2011-03","conditions":"Anorexia, Weight Changes","enrollment":1},{"nctId":"NCT00005975","phase":"PHASE3","title":"S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1998-04","conditions":"Breast Cancer, Hot Flashes","enrollment":288},{"nctId":"NCT00739830","phase":"PHASE2","title":"Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Endometrial Cancer","enrollment":130},{"nctId":"NCT02446353","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of Apetrol ES","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2010-04","conditions":"Healthy","enrollment":79},{"nctId":"NCT01943058","phase":"PHASE2","title":"Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2014-03","conditions":"Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma","enrollment":""},{"nctId":"NCT01456624","phase":"PHASE1","title":"Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fasting and Fed Condition","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2011-09","conditions":"Healthy","enrollment":56},{"nctId":"NCT01501396","phase":"PHASE2","title":"Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2013-09","conditions":"Anorexia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":833,"reaction":"DEATH"},{"count":645,"reaction":"FATIGUE"},{"count":591,"reaction":"DIARRHOEA"},{"count":523,"reaction":"DECREASED APPETITE"},{"count":515,"reaction":"ASTHENIA"},{"count":501,"reaction":"NAUSEA"},{"count":454,"reaction":"PNEUMONIA"},{"count":426,"reaction":"DYSPNOEA"},{"count":345,"reaction":"WEIGHT DECREASED"},{"count":318,"reaction":"PAIN"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20070628","type":"SUPPL","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA076721"},{"date":"20041101","type":"ORIG","sponsor":"PHARMOBEDIENT","applicationNumber":"ANDA076721"},{"date":"20140827","type":"ORIG","sponsor":"TWI PHARMS","applicationNumber":"ANDA203139"},{"date":"20200221","type":"SUPPL","sponsor":"TWI PHARMS","applicationNumber":"ANDA203139"},{"date":"20150608","type":"SUPPL","sponsor":"TWI PHARMS","applicationNumber":"ANDA203139"},{"date":"20020312","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"20020131","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"20000605","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19990520","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19980824","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19981201","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19971208","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19960816","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19960816","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"20020318","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"20010814","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"20100729","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"20020131","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19991221","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19980817","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19981125","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19980317","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19960816","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19960816","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19960816","type":"SUPPL","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"19951130","type":"ORIG","sponsor":"BARR","applicationNumber":"ANDA074621"},{"date":"20160229","type":"SUPPL","sponsor":"NOVITIUM PHARMA","applicationNumber":"ANDA077404"},{"date":"20081017","type":"SUPPL","sponsor":"NOVITIUM PHARMA","applicationNumber":"ANDA077404"},{"date":"20060216","type":"ORIG","sponsor":"NOVITIUM PHARMA","applicationNumber":"ANDA077404"},{"date":"20040504","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA075671"},{"date":"20130116","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA075671"},{"date":"20030814","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA075671"},{"date":"20021001","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA075671"},{"date":"20040223","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA075671"},{"date":"20200519","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA075671"},{"date":"20010725","type":"ORIG","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA075671"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1617,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"megestrol","genericName":"megestrol","companyName":"National Center for Research Resources (NCRR)","companyId":"national-center-for-research-resources-ncrr","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}